Technical Analysis for RPRX - Royalty Pharma plc

Grade Last Price % Change Price Change
F 36.78 -1.00% -0.37
RPRX closed up 0.13 percent on Monday, September 27, 2021, on 45 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical RPRX trend table...

Date Alert Name Type % Chg
Oversold Stochastic Weakness -1.16%
Narrow Range Bar Range Contraction -1.02%
NR7 Range Contraction -1.02%
Lower Bollinger Band Walk Weakness -1.02%
Oversold Stochastic Weakness -1.02%
Stochastic Buy Signal Bullish -1.10%
Lower Bollinger Band Walk Weakness -1.10%
Lower Bollinger Band Touch Weakness -1.10%
Oversold Stochastic Weakness -1.10%
Calm After Storm Range Contraction 1.18%
Older End-of-Day Signals for RPRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Industry Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products Biopharmaceutical Industry Drug Development Services

Is RPRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 53.23
52 Week Low 34.8
Average Volume 2,601,496
200-Day Moving Average 43.23
50-Day Moving Average 38.43
20-Day Moving Average 38.19
10-Day Moving Average 37.57
Average True Range 0.96
ADX 16.47
+DI 16.05
-DI 23.90
Chandelier Exit (Long, 3 ATRs) 37.15
Chandelier Exit (Short, 3 ATRs) 38.98
Upper Bollinger Bands 40.13
Lower Bollinger Band 36.26
Percent B (%b) 0.23
BandWidth 10.15
MACD Line -0.52
MACD Signal Line -0.37
MACD Histogram -0.1454
Fundamentals Value
Market Cap 13.59 Billion
Num Shares 366 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -59.82
Price-to-Sales 12.88
Price-to-Book 5.94
PEG Ratio -0.02
Dividend 0.60
Dividend Yield 1.62%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 37.93
Resistance 3 (R3) 37.89 37.58 37.80
Resistance 2 (R2) 37.58 37.38 37.61 37.76
Resistance 1 (R1) 37.37 37.26 37.48 37.41 37.71
Pivot Point 37.06 37.06 37.12 37.09 37.06
Support 1 (S1) 36.85 36.86 36.96 36.89 36.59
Support 2 (S2) 36.54 36.74 36.57 36.54
Support 3 (S3) 36.33 36.54 36.50
Support 4 (S4) 36.37